Departamento de Neurologia, Hospital Universitário Gaffrée E Guinle/HUGG Programa de Pós Graduação Em Neurologia da Universidade Federal Do Estado Do Rio de Janeiro (UNIRIO), 775 Mariz e Barros St, Tijuca, Rio de Janeiro, RJ, 22.270-004, Brazil.
Departamento de Radiologia, Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil.
J Neurovirol. 2022 Apr;28(2):312-318. doi: 10.1007/s13365-022-01066-3. Epub 2022 Apr 2.
Olfactory dysfunction is reported frequently in patients with coronavirus disease 2019. However, an effective treatment for this dysfunction is unknown. The present study evaluated carbamazepine as a treatment option for olfactory dysfunction based on its use in cases of neuralgia, especially of the V cranial nerve. The study included 10 patients with coronavirus disease with olfactory complaints who were part of a cohort of 172 coronavirus disease patients monitored for late neurological manifestations. Carbamazepine was administered for 11 weeks. The adverse effects reported were drowsiness (9/10) and dizziness (2/10); 9 of the 10 patients reported improved olfactory function after carbamazepine treatment. While the role of carbamazepine in the control of post-coronavirus disease olfactory dysfunction could not be confirmed in this study, the satisfactory response observed in most patients in this series suggests that further studies are warranted.
嗅觉功能障碍在 2019 冠状病毒病患者中经常报道。然而，这种功能障碍的有效治疗方法尚不清楚。本研究基于卡马西平在治疗三叉神经痛（特别是第 V 颅神经）中的应用，评估其作为治疗嗅觉功能障碍的一种选择。该研究纳入了 10 名有嗅觉主诉的 2019 冠状病毒病患者，他们是监测迟发性神经系统表现的 172 名 2019 冠状病毒病患者队列的一部分。卡马西平治疗 11 周。报告的不良反应为嗜睡（9/10）和头晕（2/10）；卡马西平治疗后，10 名患者中有 9 名报告嗅觉功能改善。虽然本研究不能证实卡马西平在控制冠状病毒病后嗅觉功能障碍方面的作用，但本系列中大多数患者的满意反应表明需要进一步研究。
